149457-89-6Relevant articles and documents
Pd(ii)-Complexes of a novel pyridinone based tripeptide conjugate: Solution and solid state studies
Bényei, Attila Csaba,Buglyó, Péter,Diószegi, Róbert,Ozsváth, András
, p. 9254 - 9267 (2020)
A novel peptide conjugate (H(L2)) incorporating N-donors of the peptide backbone and an (O,O) donor set of a hydroxypyridinone moiety is synthesized and characterized. This ambidentate chelating ligand is intended to develop Co(iii)/Pt(ii) heterobimetallic multitargeted complexes with anticancer potential. To explore its metal ion binding ability the interaction with Pd(ii) (as a Pt(ii) model but with faster ligand exchange reactions) was studied in aqueous solution by the combined use of pH-potentiometry, NMR and HR MS. In an equimolar solution H(L2) was found to bind Pd(ii) via the terminal amino group and increasing number of peptide nitrogens of the peptide backbone over a wide pH range. Around physiological pH an (N,N) and (O,O) chelated 2:2 minor species was also identified. At a 2:1 Pd(ii) to ligand ratio the formation of dinuclear species, [Pd2H-x(L2)] (x = 1-4), with high stability and with the involvement of the (O,O) chelating set of the ligand too, was demonstrated. Reaction of H3(L2)2+ with Pd(ii) in the presence of chloride ions at pH ～ 2.0 afforded [PdH(L2)Cl2]·2H2O (3) in a solid state whose molecular structure was assessed by single crystal X-ray diffraction. The structure of 3 revealed that Pd(ii) is coordinated by a (NH2, Namide) chelate of the ligand in a square planar fashion. It also indicates that under suitable conditions a 2N coordinated Pd(ii) complex can also be obtained even in the presence of four available nitrogen donors in the chelatable position in the ligand most likely due to its neutral charge and the decreased conditional stability of the amide-involved chelate(s) under acidic conditions. Reaction of H(L2) with [Co(tren)]3+ (tren = tris(2-aminoethyl)amine) revealed the exclusive coordination of (L2)-via its (O,O) chelate to the metal core while treatment of the Co-complex with Pd(ii) resulted in the formation of a Co/Pd heterobimetallic complex in solution with (NH2, Namide) chelated Pd(ii). Reaction of 3 with 9-methylguanine indicated the N7 coordination of this simple DNA model to Pd(ii) in a 1:1 ratio.
Macromolecular iron-chelators via RAFT-polymerization for the inhibition of methicillin-resistant Staphylococcus aureus growth
Li, Junpei,Olaleye, Eniola D.,Kong, Xiaole,Zhou, Tao,Ma, Yongmin,Jurach, Jagoda,Al Rugaie, Osamah,Hider, Robert C.,Zhang, Guoqing,Alsam, Selwa,Abbate, Vincenzo
, p. 64 - 72 (2016)
A series of linear poly (glycidyl methacrylate) (PGMA) polymers were synthesized via RAFT polymerization and conjugated with amine-containing 3-hydroxypyridin-4-ones (HPOs) to generate a panel of HPO-containing materials with controlled structures and spe
N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease
Guo, Jianan,Zhang, Yujia,Zhang, Changjun,Yao, Chuansheng,Zhang, Jingqi,Jiang, Xiaoying,Zhong, Zhichao,Ge, Jiamin,Zhou, Tao,Bai, Renren,Xie, Yuanyuan
, (2021/06/07)
AD is a progressive brain disorder. Because of the lack of remarkable single-target drugs against neurodegenerative disorders, the multitarget-directed ligand strategy has received attention as a promising therapeutic approach. Herein, we rationally designed twenty-nine hybrids of N-propargylamine-hydroxypyridinone. The designed hybrids possessed excellent iron-chelating activity (pFe3+ = 17.09–22.02) and potent monoamine oxidase B inhibitory effects. Various biological evaluations of the optimal compound 6b were performed step by step, including inhibition screening of monoamine oxidase (hMAO-B IC50 = 0.083 ± 0.001 μM, hMAO-A IC50 = 6.11 ± 0.08 μM; SI = 73.5), prediction of blood–brain barrier permeability and mouse behavioral research. All of these favorable results proved that the N-propargylamine-hydroxypyridinone scaffold is a promising structure for the discovery of multitargeted ligands for AD therapy.
Coumarin hybrid pyridinone amide derivative with potential anti-AD activity and preparation method and application of derivative
-
Paragraph 0098; 0101, (2020/02/27)
The invention discloses a coumarin hybrid pyridinone amide derivative and a preparation method and application thereof. The coumarin hybrid pyridinone amide derivative and pharmacologically acceptablesalt thereof are shown in the formula (I) and the formula (II), and the derivative can be used for preparing drugs for resisting the Alzheimer's disease, the Parkinson's disease or treating other diseases or symptoms by suppressing monoamine oxidase, chelating metallic iron ions, resisting A and resisting oxidation.
